Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug923 | Ciclesonide Metered Dose Inhaler [Alvesco] Wiki | 0.41 |
| drug921 | Ciclesonide Wiki | 0.41 |
| drug1543 | Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3062 | Pre-operative breast magnetic resonance imaging Wiki | 0.41 |
| drug920 | ChulaCov19 mRNA vaccine Wiki | 0.41 |
| drug1546 | Flexitouch Plus with Cellular Connectivity (FT-CC) Wiki | 0.41 |
| drug3546 | Screening digital mammography Wiki | 0.41 |
| drug4584 | modification of the planned therapeutic management Wiki | 0.41 |
| drug4020 | Tislelizumab Wiki | 0.41 |
| drug1580 | Fruquintinib Wiki | 0.41 |
| drug3545 | Screening digital breast tomosynthesis Wiki | 0.41 |
| drug1207 | Diagnostic mammography Wiki | 0.41 |
| drug3544 | Screening breast magnetic resonance imaging Wiki | 0.41 |
| drug2072 | Ketotifen 1 MG Wiki | 0.41 |
| drug927 | Clazakizumab Wiki | 0.33 |
| drug918 | Cholecalciferol Wiki | 0.20 |
| drug2620 | Normal saline Wiki | 0.17 |
| drug2916 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001943 | Breast Neoplasms NIH | 1.00 |
| D014594 | Uterine Neoplasms NIH | 0.41 |
| D014625 | Vaginal Neoplasms NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100650 | Vaginal neoplasm HPO | 0.41 |
| HP:0030416 | Vulvar neoplasm HPO | 0.41 |
| HP:0010784 | Uterine neoplasm HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030079 | Cervix cancer HPO | 0.29 |
| HP:0001004 | Lymphedema HPO | 0.29 |
| HP:0100615 | Ovarian neoplasm HPO | 0.24 |
| HP:0002664 | Neoplasm HPO | 0.07 |
Navigate: Correlations HPO
There are 6 clinical trials
This Breast Cancer Surveillance Consortium (BCSC) ADVANCE study is a large, observational pragmatic comparative effectiveness research study using high-quality, prospectively collected data from BCSC registries to generate evidence on how breast density should be integrated into decision making around breast cancer screening and preoperative diagnostic work-up. We will augment existing BCSC registry infrastructure with additional prospective data collection and collection of patient reported outcomes (PROs), CISNET modeling of long-term screening outcomes, and qualitative data from focus groups with women represented in two aims.
Description: Number of stage I or IIA cancers diagnosed within 1 year of a positive screen divided by total number of screens
Measure: Screening Benefits: Rate of early stage invasive cancer detection (Aim 1) Time: Within one year after screenDescription: Number of invasive cancer cases within 1 year of a negative screen divided by total number of screens Number of advanced cancers (stage IIB or higher) within 1 year of a screen divided by total number of screens
Measure: Screening Failures: Interval or advanced breast cancer rate (Aim 1) Time: Within one year after screenDescription: Number of positive screens divided by total number of screens
Measure: Screening Harms: Recall rate (Aim 1) Time: Within one year after screenDescription: Number of positive screens without a cancer diagnosed within 1 year divided by total number of screens
Measure: Screening Harms: False-positive (FP) recall rate (Aim 1) Time: Within one year after screenDescription: Number of screens with a biopsy recommendation and no cancer diagnosed within 1 year divided by total number of screens
Measure: Screening Harms: FP biopsy recommendation rate (Aim 1) Time: Within one year after screenDescription: Number of DCIS diagnoses within 1 year of a positive screen divided by total number of screens, reported overall and by grade
Measure: Screening Harms: Other consequences (Aim 1) Time: Within one year after screenDescription: Patient surveys targeted to determining outcomes of interest to patients
Measure: Patient Reported Outcomes (Aim 1) Time: Measured within one year post-screeningDescription: Number of women with contralateral breast cancer diagnosed within 6 months of initial diagnosis over total number of women
Measure: Rates of additional breast cancers detected (Aim 2) Time: 6 months after initial diagnosisDescription: Rate of 2nd breast cancers diagnosed within 3 years of follow-up (starting 6 months after initial diagnosis) calculated separately for ipsilateral and contralateral cancers
Measure: 3-year rate of 2nd breast cancer events (Aim 2) Time: 3 years after initial diagnosisDescription: Patient surveys targeted to determining outcomes of interest to patients
Measure: Patient Reported Outcomes (Aim 2) Time: Measured 6-18 months post-diagnosisDescription: Number of cancer cases within 1 year of positive screen divided by number of breast cancer cases
Measure: Performance Measures: Sensitivity (Aim 1) Time: Within one year after screenDescription: Number of negative screens without cancer diagnosed within 1 year of screen divided by number of screens without breast cancer
Measure: Performance Measures: Specificity (Aim 1) Time: Within one year after screenDescription: Number of cancer cases within 1 year of positive screen divided by number of positive screens
Measure: Performance Measures: Positive predictive value (Aim 1) Time: Within one year after screenDescription: Rates of unilateral mastectomy, or bilateral mastectomy, lumpectomy with reconstruction, lumpectomy without reconstruction
Measure: Definitive surgery type (Aim 2) Time: 6 months after initial diagnosisDescription: Number of women with a negative pre-operative MRI and no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women with a negative pre-operative MRI
Measure: Negative predictive value of work-up with MRI (Aim 2) Time: 6 months after initial diagnosisDescription: Number of women without a pre-operative MRI with no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women without a pre-operative MRI
Measure: Negative predictive value of work-up without MRI (Aim 2) Time: 6 months after initial diagnosisDescription: Number of core biopsies within 6 months of initial diagnosis over number of breast biopsies
Measure: Core biopsy rates (Aim 2) Time: 6 months after initial diagnosisDescription: Number of surgical biopsies within 6 months of initial diagnosis over number of breast biopsies
Measure: Surgical biopsy rate (Aim 2) Time: 6 months after initial diagnosisDescription: Number of initial benign biopsies over number of breast biopsies
Measure: Benign biopsy rate (Aim 2) Time: 6 months after initial diagnosisDescription: Breast cancers deaths averted estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Breast cancers deaths averted (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageDescription: Life-years gained estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Life-years gained (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageDescription: Overdiagnosis estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Overdiagnosis (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageThe current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.
Description: modification of the planned therapeutic management
Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy) Time: Day OThis single arm, multicenter study provides the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer who are currently receiving pertuzumab (Perjeta) and trastuzumab (Herceptin) by intravenous administration (P+H IV). The main objective is to enable continuity of care during the COVID-19 pandemic. This study will enroll approximately 400 participants with HER2+ breast cancer who have completed concurrent chemotherapy with P+H IV and are currently receiving or will be receiving maintenance therapy with pertuzumab and trastuzumab. Participants will receive treatment every 3 weeks and continue treatment unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity or participant withdrawal. Only participants with HER2+ early breast cancer will receive PH FDC SC to complete 18 cycles of dual blockade, including the P+H IV they received prior to enrolling in this study. The Sponsor may decide to terminate the study when the COVID-19 pandemic is no longer a risk for this patient population.
The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (QOL), and symptom assessment.
Description: Compare the rate of compliance (defined as the number of days device used/total study days) in patients treated with PASSIVE FT-CC and ACTIVE FT-CC.
Measure: Compliance Time: Changes between 30 days after device training and 60 days after device trainingDescription: Comparison of partially compliant and compliant arm girth in patients treated with FT-CC. Arm girth is measured in cm.
Measure: Change in Arm Girth Time: Changes between baseline, 30 days after device training, and 60 days after device trainingDescription: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC via Lymphedema Quality of Life Tool (LYMQOL ARM). Lymphedema Quality of Life Tool (LYMQOL-ARM) includes sub-scores for Function (range 10-40), Appearance (range 5-20), Symptoms (range 6-24), and Emotion (range 6-24) where lower scores represent a better outcome. It also includes an Overall QOL sub-score (range 0-10) where a higher score represents a better outcome.
Measure: Quality of Life Assessment via LYMQOL ARM Time: Changes between baseline, 30 days after device training, and 60 days after device trainingDescription: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC by via The RAND 36-Item Short Form Survey (SF-36). The RAND 36-Item Short Form Survey (SF-36) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item for perceived change in health. Min value: 0, Max value: 100. Higher scores represent a better outcome.
Measure: Quality of Life Assessment via SF-36 Time: Changes between baseline, 30 days after device training, and 60 days after device trainingDescription: Comparison of partially compliant and compliant symptoms in patients treated with FT-CC by via The Lymphedema Symptom Intensity and Distress Survey-ARM (LSIDS-A). The Lymphedema Symptom Intensity and Distress Survey is a questionnaire used to assess intensity and distress of symptoms in patients with lymphedema of the arm. This includes sub-scores for soft tissue sensation (range 0-10), neurological sensation (0-10), function, (0-10), biobehavioral (0-10), resource (0-10), sexuality (0-10), activity (0-10). Higher score represents worse outcome.
Measure: Symptoms Assessment via LSIDS-A Time: Changes between baseline, 30 days after device training, and 60 days after device trainingThe objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer. The study was a randomized : , prospective controlled trial : , and the patients were identified by coded numbers to maintain privacy. Eligible patients (111) fulfilled the criteria. Control Group: 55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen). Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment. Blood samples were obtained from all patients, and echocardiography two times for each patient at baseline and after 6 months (EF%).
Description: the serum levels of LDH, CK-MB, troponin I, TIBC, ferritin, anti-cardiolipin IgG, and, iron were done
Measure: prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines Time: 6 monthsThis is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced, refractory TNBC. This study will be conducted in 2 parts; a safety lead-in phase (Part 1) and a dose expansion phase (Part 2). The safety lead-in phase will determine the RP2D. The RP2D will be administered to 2 cohorts of patients in the expansion phase. - Cohort A: TNBC (IO-treated) - Cohort B: TNBC (IO-Naïve)
Description: To assess the safety and tolerability by monitoring AEs characterized by type, frequency, severity per NCI-CTCAE v5.0
Measure: Adverse Events by type, frequency, and severity Time: At the end of Cycle 1 (each cycle is 28 days)Description: To confirm the RP2D of fruquintinib in combination with tislelizumab
Measure: Recommended Phase 2 Dose Time: At the end of Cycle 1 (each cycle is 28 days)Description: To evaluate the objective response rate (ORR) as assessed by the investigator in subjects with advanced TNBC when treated with fruquintinib in combination with tislelizumab
Measure: Objective Response Rate Time: Up to 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports